Sugi Predict

Sugi Predict / Targets / NOTCH3

NOTCH3

Neurogenic locus notch homolog protein 3 · Q9UM47 · NOTCH3 on Sugi Atlas →

3,273 patent compounds predicted against NOTCH3, 2,161 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4412662 SCHEMBL4412662 0.59 15/20
SCHEMBL4559271 SCHEMBL4559271 0.58 15/20
SCHEMBL4558772 SCHEMBL4558772 0.57 15/20
SCHEMBL4559116 SCHEMBL4559116 0.57 15/20
SCHEMBL4558854 SCHEMBL4558854 0.53 15/20
SCHEMBL4557478 SCHEMBL4557478 0.52 15/20
SCHEMBL4559117 SCHEMBL4559117 0.52 15/20
SCHEMBL4557562 SCHEMBL4557562 0.59 14/20
SCHEMBL4558957 SCHEMBL4558957 0.56 14/20
SCHEMBL4487000 SCHEMBL4487000 0.52 14/20
SCHEMBL4487712 SCHEMBL4487712 0.53 13/20
SCHEMBL4499781 SCHEMBL4499781 0.53 13/20
SCHEMBL4499032 SCHEMBL4499032 0.52 13/20
SCHEMBL4496817 SCHEMBL4496817 0.64 12/20
SCHEMBL4471840 SCHEMBL4471840 0.62 12/20
SCHEMBL4499525 SCHEMBL4499525 0.59 12/20
SCHEMBL4490053 SCHEMBL4490053 0.59 12/20
SCHEMBL4492138 SCHEMBL4492138 0.58 12/20
SCHEMBL4494457 SCHEMBL4494457 0.57 12/20
SCHEMBL4499165 SCHEMBL4499165 0.56 12/20

Clinical trials — most relevant to NOTCH3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis PHASE2COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma PHASE1/PHASE2COMPLETED
NG2 and DLL3 CAR-T Cells Targeting Melanoma PHASE1/PHASE2RECRUITING
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery PHASE2WITHDRAWN
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma PHASE2WITHDRAWN
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study) PHASE2COMPLETED
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery PHASE1COMPLETED
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma PHASE1COMPLETED
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors PHASE1RECRUITING
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia PHASE1WITHDRAWN
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
AusCADASIL: An Australian Cohort of CADASIL nanRECRUITING
Emerging Role of NOTCH-related Long Non-coding RNA(s) as Biomarkers in Liquid Biopsy From Colorectal Cancer Patients nanCOMPLETED
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response nanCOMPLETED
CADASIL Registry Study nanRECRUITING
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo nanRECRUITING
Development of New Biomarkers With Magnetic Resonance Imaging for Longitudinal Studies in CADASIL Angiopathy nanUNKNOWN
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches. nanRECRUITING
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma nanUNKNOWN
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia nanCOMPLETED
Impact of CASP3 Gene in Chemoresistance nanNOT_YET_RECRUITING
MR Elastography in Intracranial Lesions: Feasibility & Accuracy nanACTIVE_NOT_RECRUITING
Alzheimer's Disease Neuroimaging Initiative 3 nanCOMPLETED
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents nanRECRUITING
Does Notch Regulate Glioma Proliferation ? nanCOMPLETED
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome nanCOMPLETED
B3 for NMD: Bench to Bedside and Back nanENROLLING_BY_INVITATION
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury nanUNKNOWN
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a NOTCH3 binder may also engage these)

ProteinNameSimilarity
Q61982 — 1.000 Q61982 →
Q9R172 — 0.999 Q9R172 →
NOTCH1 Neurogenic locus notch homolog protein 1 0.982 landscape →
P31695 — 0.981 P31695 →
Q9Y219 — 0.978 Q9Y219 →
O35516 — 0.977 O35516 →
Q01705 — 0.977 Q01705 →
Q07008 — 0.977 Q07008 →
Q5ZQU0 — 0.976 Q5ZQU0 →
P97607 — 0.976 P97607 →
G3I6Z6 — 0.976 G3I6Z6 →
Q9QYE5 — 0.974 Q9QYE5 →
NOTCH4 Neurogenic locus notch homolog protein 4 0.973 landscape →
Q9QW30 — 0.973 Q9QW30 →
Q70E20 — 0.972 Q70E20 →
Q8TER0 — 0.970 Q8TER0 →
Q5IJ48 — 0.969 Q5IJ48 →
NOTCH2 Neurogenic locus notch homolog protein 2 0.968 landscape →
A0A096LNW5 — 0.968 A0A096LNW5 →
Q80YA8 — 0.967 Q80YA8 →
P0DPK3 — 0.967 P0DPK3 →
Q5VY43 — 0.967 Q5VY43 →
Q75N90 — 0.966 Q75N90 →
Q90Y57 — 0.965 Q90Y57 →
P78504 — 0.965 P78504 →
Q8VIK5 — 0.964 Q8VIK5 →
Q8K1E3 — 0.964 Q8K1E3 →
O00468 — 0.963 O00468 →
P46530 — 0.963 P46530 →
Q63722 — 0.963 Q63722 →